ClinicalTrialsFinder
RecruitingPhase 2NCT04600960

Eltrombopag for Chemotherapy-induced Thrombocytopenia

Eltrombopag for Chemotherapy-induced Thrombocytopenia: a Prospective Multi-center One-arm Study in Solid Tumors

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment

50 participants

Start Date

Dec 31, 2020

Study Type

INTERVENTIONAL

Summary

To evaluate the efficacy and safety of eltrombopag to treat chemotherapy-induced thrombocytopenia in solid tumors

Eligibility

Min Age: 18 Years

Inclusion Criteria8

  • Aged ≥18 years old, male or female;
  • Conform to the diagnostic criteria of chemotherapy-induced thrombocytopenia (CIT); Ineffective after repeated treatment with rhTPO or IL-11；
  • Stop radiotherapy or chemotherapy for more than 1 month;
  • Platelet counts <30 ×10\^9/L, and bleeding tendency;
  • Estimated survival period ≥ 6 months；
  • People who are willing to sign the informed consent voluntarily and follow the research program.
  • Liver and kidney function<1.5×upper limit of normal, qualified for physical examination；
  • Subject is practicing an acceptable method of contraception. Women of childbearing potential must have a negative serum pregnancy test in the whole study;

Exclusion Criteria15

  • Those with uncontrollable primary diseases of important organs, such as extensive metastasis of malignant tumors, liver failure, heart failure, kidney failure and other diseases；
  • Patients with poor compliance;
  • Positive serology for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), and/or hepatitis D virus (HDV), Syphilis; Positive for Epstein-Barr Virus DNA, Cytomegalovirus DNA;
  • Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal bleeding, intracranial hemorrhage, etc.
  • There is currently a heart disease requiring treatment or a poorly controlled hypertension judged by the investigator；
  • Patients with thrombotic diseases such as pulmonary embolism, thrombosis, and atherosclerosis；
  • Those who have received allogeneic stem cell transplantation or organ transplantation in the past；
  • Patients with mental disorders who cannot normally obtain informed consent and undergo trials and follow-up；
  • Patients whose toxic symptoms caused by treatment before participating in the trial have not disappeared；
  • Other serious diseases that may restrict participants from participating in this trial (such as diabetes; severe heart failure; myocardial obstruction or unstable arrhythmia or unstable angina in the past 6 months; gastric ulcers; mobility Autoimmune diseases, etc.)；
  • Patients with sepsis or patients with other irregular bleeding；
  • Patients taking antiplatelet drugs at the same time；
  • Pregnant women, suspected pregnancy (a positive pregnancy test for human chorionic gonadotropin in urine at screening) and breastfeeding patients；
  • Pre-existing cardiac disease, including congestive heart failure of New York Heart Association \[NYHA\] Grade III/IV, arrhythmia requiring treatment or myocardial infarction within the last 6 months. No arrhythmia known to increase the risk of thrombotic events (e.g. atrial fibrillation), or patients with a QT >450msec or QTc > 480 for patients with a Bundle Branch Block;
  • Researchers believe that patients should not participate in the test of any other condition.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEltrombopag

The subjects will initiate treatment with 75 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 75 mg daily. Subjects whose platelet count ≤100×109/L，the eltrombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of eltrombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of eltrombopag to 25mg once every other day during the treatment period, eltrombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off eltrombopag if the platelet is greater than 50×109/L.

Locations(1)

Chinese Academy of Medical Science and Blood Disease Hospital

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04600960